Atorvastatin compared with simvastatin in the prevention of CHD morbidity and mortality in patients with CHD

Trial Profile

Atorvastatin compared with simvastatin in the prevention of CHD morbidity and mortality in patients with CHD

Completed
Phase of Trial: Phase IV

Latest Information Update: 05 Nov 2016

At a glance

  • Drugs Atorvastatin (Primary) ; Simvastatin
  • Indications Coronary disorders; Heart failure; Myocardial infarction
  • Focus Therapeutic Use
  • Acronyms IDEAL
  • Sponsors Pfizer
  • Most Recent Events

    • 04 Nov 2016 Results of post-hoc analysis published in the American Journal of Cardiology.
    • 05 Apr 2011 Results of a pharmacogenomic analysis presented in combination with results from the TNT study at the 60th Annual Scientific Session of the American College of Cardiology.
    • 29 Aug 2006 Status change
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top